Browse the evidence

GLP-1 receptor agonists (GLP-1 RAs) promote significant, sustained weight loss in adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with comorbidities, primarily through central nervous system-mediated appetite suppression and reduced caloric intake, with efficacy superior to previously approved anti-obesity medications.

GLP-1 agonists like semaglutide and liraglutide are FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. They work by targeting hormonal pathways in the brain to reduce hunger and increase satiety, leading to significant, sustained weight loss that is roughly double that of older medications. Treatment is available in daily or weekly injectable forms, as well as oral tablets, and is intended for long-term use to maintain results without the 'Yo-Yo' effect common with short-term diets.

Replacing saturated fat with either monounsaturated or polyunsaturated fat significantly lowers total and LDL cholesterol, with no significant difference in efficacy between the two unsaturated fat types.

To lower your LDL cholesterol, swap saturated fats (like butter or fatty meat fat) for unsaturated fats. You can use monounsaturated oils (olive, canola) or polyunsaturated oils (corn, sunflower, safflower). The paper shows they work equally well for lowering LDL. Focus on the substitution itself rather than choosing one specific 'premium' oil over another for lipid benefits.

In older adults (mean age ≥50 years) undergoing energy-restricted weight loss, consuming higher protein diets (≥1.0 g/kg/d or ≥25% of energy) preserves lean mass and increases fat mass loss compared to normal protein intakes (<1.0 g/kg/d or <25% of energy).

If you are an older adult trying to lose weight, ensure your protein intake is at least 1.0 gram per kilogram of body weight per day (or makes up at least 25% of your calories). This strategy helps you lose more fat and keep more muscle compared to eating less protein, without needing to change your exercise routine.

Metabolic surgery (RYGB, SG, BPD) is superior to medical management for achieving type 2 diabetes remission and glycemic control in patients with BMI ≥35 kg/m², with remission rates significantly higher than lifestyle or pharmacological interventions alone.

If you have Type 2 Diabetes and obesity (BMI ≥35), metabolic surgery is currently the most effective treatment for achieving remission, far outperforming diet and medication alone. While surgery carries risks, modern techniques have made it as safe as common procedures like gallbladder removal. Consult a bariatric surgeon to evaluate if you are a candidate.

Maintaining a body mass index (BMI) of 23.0–24.9 or higher at age 21, or gaining 2.5 kg or more during adulthood, significantly increases the risk of major chronic diseases (type 2 diabetes, cardiovascular disease, and obesity-related cancers) in men.

For men, keeping a BMI below 23 at age 21 and avoiding adult weight gain are critical for preventing diabetes, heart disease, and certain cancers. Even 'modest' overweight or small weight gains (2.5+ kg) significantly increase risk, so maintaining a leaner early-adulthood weight is a high-leverage health strategy.

Adherence to a Mediterranean diet (MedDiet) is associated with reduced body weight, lower BMI, and a decreased risk of incident overweight or obesity compared to control diets or low-adherence groups.

Adopt a Mediterranean-style eating pattern as your default. Focus on daily consumption of vegetables, fruits, whole grains, legumes, nuts, and olive oil. Eat fish 2-3 times a week and limit red/processed meats and sweets. You do not need to count calories strictly, but prioritize whole, minimally processed foods. This approach is sustainable, tasty, and has strong evidence for preventing weight gain and obesity.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily) produce significant weight loss in adults with obesity without diabetes, with semaglutide demonstrating superior efficacy compared to liraglutide.

For adults with obesity without diabetes, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are effective weight loss treatments. Semaglutide offers greater weight reduction than liraglutide. These drugs work by mimicking a hormone that increases satiety and slows digestion. Common side effects include gastrointestinal issues, which are often managed by starting with a lower dose and gradually increasing it.

Lowering blood pressure in Type 2 Diabetes patients reduces the risk of cerebrovascular accidents and congestive heart failure, with ACE inhibitors or ARBs recommended as first-line therapy.

Keep your blood pressure below 140/80 mmHg using ACE inhibitors or ARBs as your first medication. This is crucial for preventing strokes and heart failure in Type 2 Diabetes.

Personal coaching enhanced by mobile self-monitoring produces significant short-term weight loss (6 months) in young adults compared to control, but this effect is not sustained at 12 or 24 months.

Personal coaching can help you lose weight in the short term, but it may not be enough to keep it off long-term. To maintain weight loss, you might need more frequent coaching, more sessions, or a combination of coaching and technology that adapts to your needs over time.

GLP-1 receptor agonists provide superior clinical outcomes compared to insulin in type 2 diabetes, offering better glycemic control, significant weight loss, and reduced hypoglycemia risk.

For type 2 diabetics struggling with oral meds, switching to a GLP-1 receptor agonist (like semaglutide or dulaglutide) is clinically superior to starting insulin. You will likely lose weight, have lower blood pressure, and avoid dangerous low-blood-sugar episodes, while achieving better or equal blood sugar control. These drugs are easier to use (up to once weekly) and do not require the complex titration of insulin.

GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produce significant, sustained weight reduction in adults with obesity by acting on the gut-brain axis to reduce appetite and food intake.

Semaglutide 2.4 mg injected once weekly, combined with lifestyle counseling, leads to an average 14.9% body weight loss in adults with obesity over 68 weeks. Side effects like nausea are common initially but typically subside; starting with a lower dose helps manage this.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces greater weight reduction than GLP-1 monotherapy in individuals with obesity without type 2 diabetes.

Tirzepatide 15 mg injected once weekly leads to an average 20.9% body weight loss in adults with obesity without diabetes over 72 weeks. This dual-action hormone therapy is more effective than GLP-1 monotherapy.

Adherence to a diet high in fruit, vegetables, nuts, legumes, fish, and whole-fat dairy is associated with significantly lower all-cause mortality and cardiovascular disease risk across diverse global populations, particularly in lower-income countries.

Focus your daily diet on increasing the intake of six specific food groups: fruits, vegetables, legumes, nuts, fish, and whole-fat dairy. Aim to consume these foods in amounts that exceed the median intake of your local population. This pattern is associated with a 30% lower risk of death and an 18% lower risk of cardiovascular events. This is particularly impactful in lower-income regions where these foods are less commonly consumed.

Mediterranean, DASH-style, pescetarian, and ovo/lacto-vegetarian dietary patterns, when implemented as intended, strongly align with 2021 AHA Dietary Guidance and support optimal cardiovascular health.

Adopt a Mediterranean, DASH, pescetarian, or vegetarian diet as your primary way of eating. Focus on vegetables, fruits, whole grains, and healthy fats like olive oil. If you eat animal products, choose lean meats, fish, or low-fat dairy. This approach is flexible, culturally adaptable, and strongly supported by heart health guidelines.

Tight blood-glucose control via traditional therapies does not significantly reduce macrovascular outcomes or heart failure risk in type 2 diabetes, whereas SGLT2 inhibitors and GLP-1 agonists significantly reduce cardiovascular mortality and heart failure hospitalization.

If you have Type 2 Diabetes and are at risk for heart issues, simply keeping your blood sugar numbers low with older medications may not protect your heart. Current guidelines recommend using specific newer medications (SGLT2 inhibitors or GLP-1 agonists) because they have proven to reduce the risk of heart failure and cardiovascular death, independent of their glucose-lowering effects. Discuss these specific classes with your doctor.

High-quality carbohydrate diets (emphasizing whole grains, pulses, fruit, low glycemic index/load, and high viscous fiber) decrease intermediate cardiometabolic risk factors and are associated with reduced incidence of diabetes, cardiovascular disease, and mortality, whereas low-carbohydrate diets show no long-term superiority for weight loss or sustained glycemic control.

Focus on the quality of carbohydrates rather than restricting their quantity. Prioritize whole grains (especially oats and barley), pulses, fruit, and high-fiber foods. Limit sugar-sweetened beverages. This approach is associated with better long-term weight management and reduced risk of diabetes and heart disease compared to low-carbohydrate diets.

Weight loss of 10% or greater is associated with clinically significant improvements in asthma control (ACQ scores) in obese adults with uncontrolled asthma, whereas modest weight loss (<10%) is not.

For obese individuals with uncontrolled asthma, losing 10% or more of their body weight is likely to result in meaningful improvements in asthma control. Losing less than 10% may not provide enough benefit to change asthma symptoms, even if it helps other health markers. This suggests that asthma management in obesity may require more aggressive weight loss strategies than standard lifestyle advice.

Second-generation anti-obesity medications (semaglutide 2.4 mg and tirzepatide) induce significantly greater weight loss (15-21%) compared to traditional lifestyle modification (5-10%) by pharmacologically enhancing satiation and reducing hunger, thereby decreasing the reliance on cognitive behavioral strategies for calorie restriction.

If you have obesity, second-generation medications like semaglutide or tirzepatide are significantly more effective than lifestyle changes alone, producing 15-21% weight loss compared to 5-10%. They work by reducing hunger and increasing fullness, which reduces the mental effort needed to restrict calories. While they require weekly injections and gradual dose titration to manage side effects, they represent a major advancement in obesity treatment.

Dietary guidelines should prioritize overall diet quality and minimally processed foods over isolated nutrient targets (such as total fat or calories) to effectively prevent chronic disease and obesity.

Stop obsessing over single nutrients like total fat or strict calorie counting. Instead, build your diet around minimally processed, nutrient-dense foods like vegetables, fruits, nuts, seeds, beans, whole grains, and healthy oils. Actively avoid ultra-processed foods high in refined sugars, starches, and industrial additives like trans fats.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered via once-weekly subcutaneous injections, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 agonists, and basal insulin.

Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to help your pancreas release insulin when needed, slow down digestion, and reduce appetite. It is prescribed for type 2 diabetes and obesity. Clinical trials show it lowers blood sugar and body weight more effectively than many existing diabetes and weight-loss medications. Common side effects include nausea and diarrhea, which usually improve over time. It is taken alongside diet and exercise changes.

GLP-1 Receptor Agonists (GLP-1 RA) and SGLT-2 Inhibitors (SGLT-2i) provide significant cardiovascular and renal benefits, with GLP-1 RAs also offering substantial weight loss and HbA1c reduction.

Consider GLP-1 RAs or SGLT-2 inhibitors if you need better blood sugar control, weight loss, or heart protection. These drugs have strong evidence for reducing heart attacks and strokes. Be aware of potential stomach issues, which often improve over time.

Sustained weight loss of 5-10% or greater through negative energy balance interventions (behavioral, pharmacological, or surgical) prevents, reduces, or resolves obesity-related complications such as type 2 diabetes, hypertension, and fatty liver disease.

To significantly lower your risk of type 2 diabetes and other obesity-related diseases, you need to achieve and maintain a weight loss of at least 5-10% of your body weight. This can be done through lifestyle changes, medications, or surgery. The key is that the weight loss must be sustained over the long term, not just short-term dieting.

Greater magnitude of weight loss (e.g., >10-15%) is required to achieve remission of type 2 diabetes, whereas moderate weight loss (5-10%) is sufficient for prevention or delay.

If you want to prevent type 2 diabetes, losing 5-10% of your body weight is a great start. However, if you already have type 2 diabetes and want to achieve remission, you likely need to lose more than 10-15% of your body weight and keep it off.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater body weight loss and higher rates of prediabetes-to-normoglycemia conversion compared to GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and placebo in non-diabetic obese individuals.

If you have obesity or are overweight without diabetes, a once-weekly dual-acting injection (tirzepatide) can lead to significant weight loss (up to 21% in trials) and often reverses prediabetes. This is more effective than older GLP-1 drugs. It requires lifestyle changes alongside the medication.